Why Homology Medicines Might Be a Game Changer for Gene Therapy - podcast episode cover

Why Homology Medicines Might Be a Game Changer for Gene Therapy

Jul 06, 201617 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Gene therapy is offering rare disease patients the promise of delivering potential cures, but as it is generally approached today it has technical challenges to overcome, manufacturing complexities, and an expected high cost. Homology Medicines is taking a unique approach to gene therapy that makes use of a special set of viral vectors that gets around many of the obstacles other gene therapies face. We spoke to Arthur Tzianabos, CEO of Homology Medicines, about the company’s gene therapy, how it’s unique, and why its production and cost may be similar to other biologics today.
For the best experience, listen in Metacast app for iOS or Android